Weight loss drug semaglutide approved for NHS use

The BBC has reported that a weight loss jab that has gained popularity in the US has been approved for use by the NHS in England.

The National Institute for Health and Care Excellence (NICE) concluded that semaglutide, marketed as Wegovy, is safe, effective and affordable. Delivered via an injection into the skin, the drug makes people feel fuller and more satisfied, so they eat less.

Based on evidence from clinical trials, NICE says semaglutide could help people reduce their weight by over 10%, if implemented alongside nutrition and lifestyle changes.

It will be recommended for use by people with at least one weight-related health condition, as well as those who have a body mass index (BMI) which puts them near the top of the obese range. Those who are lower on the obese BMI range – a BMI between 30 and 34.9kg/m2 – could also be offered the drug if they have a weight-related health condition, including if they are pre-diabetic, have Type 2 diabetes, high blood pressure, heart disease or obstructive sleep apnoea.

To read more, CLICK HERE.

Desang Diabetes Magazine is our free-to-receive digital journal (see below). We cover diabetes news, diabetes management equipment (diabetes ‘kit’ such as insulin pumps and continuous glucose monitoring equipment) and news about food suitable for a diabetic diet including a regular Making Carbs Count column. We just need your email address to subscribe you (it really is free, and you can easily unsubscribe should you wish to).

Sign me up!
Open publication
Buy a Desang kitbag

See our range of kitbags